AQR Capital Management
ORIC icon

AQR Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

AQR Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.89M Buy
358,751
+188,664
+111% +$1.71M ﹤0.01% 2165
2026
Q1 		$2.16M Sell
170,087
-4,192
-2% -$47.6K ﹤0.01% 2300
2025
Q4 		$1.43M Buy
174,279
+2,354
+1% +$27.1K ﹤0.01% 2349
2025
Q3 		$2.06M Buy
171,925
+492
+0.3% +$5.18K ﹤0.01% 1963
2025
Q2 		$1.74M Buy
171,433
+121,903
+246% +$818K ﹤0.01% 1865
2025
Q1 		$276K Buy
+49,530
New +$433K ﹤0.01% 2727
2024
Q3 		– Sell
-12,241
Closed -$86.5K – 2848
2024
Q2 		$86.5K Sell
12,241
-2,057
-14% -$18.4K ﹤0.01% 2508
2024
Q1 		$197K Buy
14,298
+152
+1% +$1.8K ﹤0.01% 2255
2023
Q4 		$130K Buy
14,146
+2,947
+26% +$21.3K ﹤0.01% 2264
2023
Q3 		$67.8K Buy
+11,199
New +$91.8K ﹤0.01% 2267
2022
Q3 		– Sell
-12,508
Closed -$56K – 2282
2022
Q2 		$56K Buy
+12,508
New +$49.9K ﹤0.01% 2127

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management's ORIC Position: Q2 2026 in Review

AQR Capital Management increased its Oric Pharmaceuticals (ORIC) stake by 111% in Q2 2026, buying an estimated $1.71M and bringing the position to 358,751 shares worth $3.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2165.

AQR Capital Management first reported a position in ORIC in Q2 2022 and has held it in 11 quarters since. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • AQR Capital Management held 358,751 shares of Oric Pharmaceuticals worth $3.89M as of Q2 2026.
  • AQR Capital Management bought 188,664 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.71M.
  • Oric Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2165 holding.
  • AQR Capital Management first reported a position in Oric Pharmaceuticals in Q2 2022 and has held it in 11 quarters since.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.